C

China Resources Pharmaceutical Group Ltd
HKEX:3320

Watchlist Manager
China Resources Pharmaceutical Group Ltd
HKEX:3320
Watchlist
Price: 5.57 HKD 1.27% Market Closed
Market Cap: 35B HKD
Have any thoughts about
China Resources Pharmaceutical Group Ltd?
Write Note

China Resources Pharmaceutical Group Ltd
Total Current Liabilities

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

China Resources Pharmaceutical Group Ltd
Total Current Liabilities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Total Current Liabilities CAGR 3Y CAGR 5Y CAGR 10Y
C
China Resources Pharmaceutical Group Ltd
HKEX:3320
Total Current Liabilities
HK$144B
CAGR 3-Years
1%
CAGR 5-Years
5%
CAGR 10-Years
N/A
G
Grand Pharmaceutical Group Ltd
HKEX:512
Total Current Liabilities
HK$6.4B
CAGR 3-Years
13%
CAGR 5-Years
9%
CAGR 10-Years
8%
U
United Laboratories International Holdings Ltd
HKEX:3933
Total Current Liabilities
ÂĄ7.4B
CAGR 3-Years
10%
CAGR 5-Years
-2%
CAGR 10-Years
0%
Sino Biopharmaceutical Ltd
HKEX:1177
Total Current Liabilities
ÂĄ21.9B
CAGR 3-Years
24%
CAGR 5-Years
17%
CAGR 10-Years
21%
C
China Traditional Chinese Medicine Holdings Co Ltd
HKEX:570
Total Current Liabilities
ÂĄ9.9B
CAGR 3-Years
4%
CAGR 5-Years
-2%
CAGR 10-Years
23%
H
HUTCHMED (China) Ltd
HKEX:13
Total Current Liabilities
$373.3m
CAGR 3-Years
15%
CAGR 5-Years
28%
CAGR 10-Years
18%
No Stocks Found

China Resources Pharmaceutical Group Ltd
Glance View

Market Cap
35B HKD
Industry
Pharmaceuticals

In the vast and dynamic landscape of China's healthcare sector, China Resources Pharmaceutical Group Ltd. has emerged as a formidable player. Born from the rich heritage of its parent conglomerate, China Resources Holdings, the company weaves together a complex tapestry of pharmaceutical manufacturing, distribution, and retail operations. Its diversified operations ensure that it maintains a robust footprint across the entire pharmaceutical value chain. The company's manufacturing arm is a powerhouse, producing a vast array of products, including traditional Chinese medicine and modern pharmaceuticals, catering to the diverse needs of health consumers in China and beyond. Leveraging its extensive industry expertise and a deep understanding of the local market, China Resources Pharmaceutical crafts products that blend innovation with time-honored traditions, effectively meeting the growing demands for quality healthcare solutions. On the distribution and retail front, China Resources Pharmaceutical Group employs its extensive and well-integrated network to efficiently channel its products across the nation. The strategic positioning of its distribution centers enables it to serve hundreds of thousands of pharmacies, hospitals, and healthcare institutions, ensuring broad accessibility. Retail operations round out the company's comprehensive approach, with a wide-reaching chain of drugstores under its banner offering not only medicinal products but also healthcare services. This holistic business model not only diversifies revenue streams but also strengthens the company's ability to weather industry shifts, making it a resilient entity in the ever-evolving pharmaceutical and healthcare milieu. Through its multifaceted approach, China Resources Pharmaceutical Group Ltd. continues to play a crucial role in shaping the future of healthcare in China, navigating challenges and opportunities with the acuity expected of an industry leader.

Intrinsic Value
16.42 HKD
Undervaluation 66%
Intrinsic Value
Price
C

See Also

What is China Resources Pharmaceutical Group Ltd's Total Current Liabilities?
Total Current Liabilities
144B HKD

Based on the financial report for Jun 30, 2024, China Resources Pharmaceutical Group Ltd's Total Current Liabilities amounts to 144B HKD.

What is China Resources Pharmaceutical Group Ltd's Total Current Liabilities growth rate?
Total Current Liabilities CAGR 5Y
5%

Over the last year, the Total Current Liabilities growth was 0%. The average annual Total Current Liabilities growth rates for China Resources Pharmaceutical Group Ltd have been 1% over the past three years , 5% over the past five years .

Back to Top